Target intelligence / Profile preview

Presenilin enhancer protein 2–lysosomal vacuolar-type H+-ATPase complex (PEN-2–v-ATPase)

Target
PEN-2–v-ATPase
Molecular classification
Protein complex, Enzyme, Ion transporter, Receptor
01

Overview

The Presenilin enhancer protein 2–lysosomal vacuolar-type H+-ATPase complex is a multi-protein assembly that serves as a pivotal hub for cellular energy sensing and lysosomal maintenance [1]. Presenilin enhancer 2 (PEN-2), traditionally recognized as a core subunit of the gamma-secretase complex, has been recently identified as a direct sensor for glucose on the lysosomal membrane [2]. Under conditions of glucose starvation, the absence of glucose binding allows PEN-2 to interact with the ATP6V1A subunit of the vacuolar-type H+-ATPase (v-ATPase), which triggers the recruitment of the AXIN-LKB1 complex to activate AMP-activated protein kinase (AMPK) [1, 4]. Beyond its role in metabolic signaling, this complex is essential for maintaining the acidic environment of the lysosome, which is required for the degradation of cellular waste via autophagy [2]. Impairment of the PEN-2–v-ATPase interaction is linked to the pathogenesis of Alzheimer's disease, as it leads to lysosomal alkalization and the accumulation of amyloid-beta and tau aggregates [3]. Consequently, this complex represents a novel therapeutic target for both metabolic diseases and neurodegeneration, offering a mechanism to modulate energy balance and enhance proteostatic clearance [1, 4].

Other names
PEN2-v-ATPase complexPSENEN-v-ATPase complexPresenilin enhancer 2-vacuolar H+-ATPase complexPEN-2–v-ATPase–AMPK complex
02

Mechanism of action

Glucose-dependent recruitment of the AXIN-LKB1 complex to the v-ATPase for AMPK activation and regulation of lysosomal pH.

03

Biological functions

Glucose sensingLysosomal acidificationAMPK signalingAutophagyProteolysisMetabolic regulation
04

Disease associations

Alzheimer's diseaseType 2 diabetesMetabolic syndromeNeurodegenerative disease
05

Safety considerations

Notch signaling toxicity (due to PEN-2 role in gamma-secretase)Systemic metabolic dysregulationPotential for off-target effects on other v-ATPase-dependent organelles
06

Interacting drugs

Glucose

1 more in the full profile.

07

Biomarkers

Phosphorylated AMPK (p-AMPK)Lysosomal pHp62/SQSTM1 levelsAmyloid-beta levels

Beyond the preview

Go deeper on Presenilin enhancer protein 2–lysosomal vacuolar-type H+-ATPase complex (PEN-2–v-ATPase).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Presenilin enhancer protein 2–lysosomal vacuolar-type H+-ATPase complex (PEN-2–v-ATPase).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call